Carrageenans from Sarcothalia crispata and Gigartina skottsbergii: Structural Analysis and Interpolyelectrolyte Complex Formation for Drug Controlled Release
- 133 Downloads
The aims of the present study were to characterize for the first time the carrageenan extracted from cystocarpic stage of S. crispata collected in the Patagonian coast of Argentina, and to prepare interpolyelectrolytic complexes (IPECs) between the polysaccharide extracted from cystocarpic stage of Sarcothalia crispata and Gigartina skottsbergii thalli, and basic butylated methacrylate copolymer (Eudragit E), in order to test their potential for the controlled release of ibuprofen as model drug. The structural determination revealed that the polysaccharides extracted from S. crispata and G. skottsbergii were mainly constituted by κ-carrageenan, particularly in the case of G. skottsbergii; however, significant amounts of ι- and ν-carrageenan were also detected in both polygalactans. The differences in diad composition and possibly in their distribution along the polysaccharide chain of both carrageenans would favor a different arrangement in the resulting IPEC structure. The smaller pores observed by scanning electron microscopy in the IPEC of S. crispata suggest that the kinks in the polysaccharide backbone are evenly distributed, resulting in a slower ibuprofen release compared to the IPEC of G. skottsbergii.
KeywordsSarcothalia crispata Gigartina skottsbergii Carrageenan IPECs Controlled drug release
The authors are indebted to Consejo Nacional de Investigaciones Científicas y Técnicas de la República Argentina (CONICET) PIP 112-201101-00208 and 112-2015 01-00510, Secretaría de Ciencia y Tecnología de la Universidad Nacional del Sur, PGI 24/B246 and Secretaría de Ciencia y Técnica, Universidad de Buenos Aires, UBACyT 20020130100216BA. MHH is a Fellow Member of CONICET. HJP, PIL, and MCM are Research Members of CONICET.
Compliance with Ethical Standards
Conflict of Interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- Digimizer (2018) Image analysis software version 5.3.3. MedCalc Software bvba, Ostend, Belgium. https://www.digimizer.com/
- Khan AK, Saba AU, Nawazish S, Akhtar F, Rashid R, Mir S, Nasir B, Iqbal F, Afzal F, Pervaiz F, Murtaza G (2017) Carrageenan based bionanocomposites as drug delivery tool with special emphasis on the influence of ferromagnetic nanoparticles. Oxidative Med Cell Longev. 1–13Google Scholar
- Lowman MA (2000) In: Wise DL (ed) Handbook of pharmaceutical controlled release technology. Marcel Dekker, New YorkGoogle Scholar
- McHugh DJ (2003) A guide to the seaweed industry FAO Fisheries Technical Paper 441. Food and Agriculture Organization of the United Nations, RomeGoogle Scholar
- Moustafine RI, Salachova AR, Frolova ES, Kemenova VA, van den Mooter G (2009) Interpolyelectrolyte complexes of Eudragit E PO with sodium alginate as potential carriers for colonic drug delivery: monitoring of structural transformation and composition changes during swell ability and release evaluating. Drug Dev Ind Pharm 35:1439–1451CrossRefGoogle Scholar
- Moustafine RI, Sitenkova AY, Bukhovetsa AV, Nasibullina SF, Appeltans B, Kabanova TV, Khutoryanskiy VV, Van den Mooter G (2017) Indomethacin-containing interpolyelectrolyte complexes based on Eudragit1 E PO/S 100 copolymers as a novel drug delivery system. Int J Pharm 524:121–133CrossRefGoogle Scholar
- Peppas NA (1985) Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:100–111Google Scholar
- Rees DA, Morris ER, Thom D, Marden JK (1982) In: Aspinall GO (ed) The polysaccharides, vol 1. Academic Press, Inc, New YorkGoogle Scholar
- Stortz CA, Cerezo AS (2000) Novel findings in carrageenans, agaroids and “hybrid” red seaweed galactans. Curr Top Phytochem 4:121–134Google Scholar